Júlio Souza dos-Santos

I’m proud to finish my PhD story on a high note. My paper is now published @jlb_journal , where we highlight the IL-17/IFN-γ dichotomy in γδ T cells during L. amazonensis infection. #gdTcells #LoveStory #Science academic.oup.com/jleukbio/advan…

Nature research paper: Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion go.nature.com/4dINEsy

MHC class I on target cells regulates CD4+ T cell-mediated immunity @NatImmunol nature.com/articles/s4159… @BCMFromtheLabs

Spinal cord injury patients are scrambling for access to a new paralysis therapy, but researchers say preliminary evidence is weak. scim.ag/4ryhAuA

IL-17RA signaling promotes the dedifferentiation of Paneth progenitors through ADAM17 to regenerate gut epithelium post-irradiation @NatureComms #Abs1" target="_blank" rel="nofollow noopener">nature.com/articles/s4146… @ckempen32 @stonybrooku

@biorxivpreprint Addition of DMSO to T cell cultures skews differentiation towards a memory phenotype biorxiv.org/content/10.648… @eliendebousser @ResearchUGent 🇧🇪

Boa parte dos pós-graduandos vive hoje em jornada dupla, porque ninguém consegue sobreviver dignamente em cidades grandes com as bolsas da CAPES e do CNPq. O impacto disso na formação e na produtividade da pessoa é muito significativo. E quem decide finge que não vê.

Memory loss is fuelled by gut microbes in ageing mice nature.com/articles/d4158… @Nature @ChristophThaiss @MaayanLevyPhD @Stanford @ArcInstitute nature.com/articles/d4158… nature.com/articles/s4158…

TRIFosomes found😀. Very proud of our team’s work to identify endogenous TRIFosome. Surprisingly whilst TRIFosomes activate NFKB, IFN signaling is from monomeric or dimeric TRIF. doi.org/10.1126/sciadv…

@biorxivpreprint Macrophage-derived extracellular vesicles promote T cell-dependent inflammatory pain resolution @DrexelMedicine biorxiv.org/content/10.648…

We report in Nature Medicine that the single-dose Butantan dengue vaccine showed 65% efficacy against symptomatic dengue and 80.5% protection against severe disease over 5 years, with a favorable safety profile in participants aged 2–59 in Brazil.

@biorxivpreprint GFI1 functions as a novel regulator of Vγ6+ γδT17 precursor cells restricting their peripheral expansion by acting upstream of a MAF dependent regulatory network biorxiv.org/content/10.648… @ircm_mtl 🇨🇦

PD-1 protects expanding human T cells from premature restimulation-induced cell death by modulating TCR and CD28 signaling nature.com/articles/s4141…

Online now: Effector differentiation by stem-like intraepithelial γδ T cells is required for host defense against infection dlvr.it/TR8vYz

Early exposure to Siblings with CD alters gut microbiota and increases disease risk @RirongChen @The_GEMProject @KenCroitoru @TurpinWilliams @SinaiHealth @UofTGastroHep @annegri50789035 @guthealthmd @datadriven_tdoc

Another amazing Brazilian scientist, Dr. Mariangela Hungria, a microbiologist at Embrapa's soybean research center, spent decades studying bacteria that pull nitrogen from the air and feed it to plants. The result: Brazil went from importing nitrogen fertilizer to becoming the world's largest soybean exporter — using microbes instead of chemicals. Her work won the 2025 World Food Prize. But the real prize is the 40% reduction in synthetic fertilizer use across Brazilian agriculture. This isn't just about soybeans. It's about a different model of agriculture: partner with biology instead of dominating it. The Global South has something to teach the world here

Auguries of adaptivity: LES γδ TCR ligand recognition revisited dlvr.it/TR35NR

🚨 BREAKING: Brazil just gave away a breakthrough invention because it couldn't pay a patent fee. Dr. Tatiana Sampaio drops a bombshell: The "Polilaminina" — a revolutionary material developed at Brazil's top federal university — is now anyone's to claim. Why? Budget cuts in 2015-2016 left UFRJ too broke to renew the international patent. Translation: Years of research. Millions in public investment. Gone. Because the government couldn't spare the maintenance fees. Now foreign companies can patent it themselves — and Brazil will pay them to use what it invented. This is what "austerity" actually costs.

Insights: Frosio and Ostuni @MyUniSR discuss study by Gorin et al. (hubs.la/Q043CjJY0) which reveals an unexpected mechanism by which IFN-γ sustains trained immune states through prolonged signaling driven by cytokine retention at the cell surface. hubs.la/Q043CjzR0

Adoptive γδ T cell therapy controls cytomegalovirus infection in preclinical transplantation models @NatureComms @LionelCouzi @CHUBordeaux @GabrielMarseres 🇫🇷 nature.com/articles/s4146…

CAR-T cell therapy reshaped cancer treatment over the past decade. @corina_amor_MD's lab at Cold Spring Harbor is pointing the same technology at aging, engineering CAR-T cells to recognize and eliminate senescent cells. Impetus was the lab’s first grant. Two papers in @NatureAging show what's come from it. Amor et al. showed that a single dose of senolytic CAR T cells provided lasting protection against age-related metabolic decline in mice. Then Eskiocak et al. took the same platform to the gut, demonstrating that anti-uPAR CAR-T cells could reverse aging-associated defects in intestinal regeneration and fitness. An early bet on a great lab that produced an innovative new cell therapy platform, and a body of published work the rest of the field can build on.